Drug Trial Radar · NCT01663402
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
Last checked: Nov 19, 2026Latest source record: Mar 18, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18,924
Actual
Start
Oct 2012
Primary completion
Jan 23, 2018
Study completion Jan 23, 2018
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Aug 13, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To compare the effect of alirocumab with placebo on the occurrence of cardiovascular (CV) events (composite endpoint of coronary heart disease (CHD) death, non-fatal myocardial infarction (MI), fatal and non-fatal ischemic stroke, unstable angina (UA) requiring hospitalization) in participants who experienced an acute coronary syndrome (ACS) event 4 to 52 weeks prior to randomization and were treated with evidence-based medical and dietary management of dyslipidemia. Secondary Objectives: * To evaluate the effect of alirocumab on secondary endpoints (any CHD event , major CHD event, any CV event, composite of all cause mortality/non-fatal MI/non-fatal ischemic stroke, CHD deaths, CV deaths, all cause mortality). * To evaluate the safety and tolerability of alirocumab. * To evaluate the effect of alirocumab on lipid parameters.
Conditions
- Atherosclerotic Cardiovascular Disease
Interventions
AlirocumabDrug
Alirocumab administered as SC injection of 1 mL in the abdomen or thigh with a disposable auto-injector.
PlaceboDrug
Placebo matched to alirocumab administered as a SC injection of 1 mL in the abdomen or thigh with a disposable auto-injector.
LMTDrug
Statins (atorvastatin or rosuvastatin) at stable maximal tolerated dose of statin with or without other LMT as clinically indicated.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to First Occurrence of Major Adverse Cardiovascular Event (MACE); Percentage of Observed Participants With Outcome Measure Events During the StudyTime frame: From randomization up to 64 months
Locations
1,388 sites in 57 countries. Site status is shown where the registry gives one.
Investigational Site Number 840163
Birmingham, Alabama
Investigational Site Number 840060
Birmingham, Alabama
Investigational Site Number 840117
Huntsville, Alabama
Investigational Site Number 840192
Huntsville, Alabama
Investigational Site Number 840121
Mobile, Alabama
Investigational Site Number 840319
Mobile, Alabama
Investigational Site Number 840332
Atlantis, Arizona
Investigational Site Number 840320
Newport Beach, Arizona
Investigational Site Number 840103
Tucson, Arizona
Investigational Site Number 840084
Tucson, Arizona
Investigational Site Number 840139
Banning, California
Investigational Site Number 840286
Beverly Hills, California
Investigational Site Number 840246
Beverly Hills, California
Investigational Site Number 840353
Beverly Hills, California
Investigational Site Number 840341
Carmichael, California
Investigational Site Number 840299
Chula Vista, California
Investigational Site Number 840164
Fresno, California
Investigational Site Number 840076
Fullerton, California
Investigational Site Number 840073
Huntington Beach, California
Investigational Site Number 840092
La Jolla, California
Investigational Site Number 840208
Long Beach, California
Investigational Site Number 840068
Long Beach, California
Investigational Site Number 840269
Los Alamitos, California
Investigational Site Number 840009
Los Angeles, California
Investigational Site Number 840282
Los Angeles, California
Investigational Site Number 840019
Mission Viejo, California
Investigational Site Number 840336
Moreno Valley, California
Investigational Site Number 840124
Northridge, California
Investigational Site Number 840251
Pasadena, California
Investigational Site Number 840289
Pasadena, California
Investigational Site Number 840312
Port Hueneme, California
Investigational Site Number 840261
San Diego, California
Investigational Site Number 840310
San Diego, California
Investigational Site Number 840024
San Diego, California
Investigational Site Number 840071
Santa Ana, California
Investigational Site Number 840236
Santa Rosa, California
Investigational Site Number 840012
Torrance, California
Investigational Site Number 840096
Aurora, Colorado
Investigational Site Number 840037
Colorado Springs, Colorado
Investigational Site Number 840189
Denver, Colorado
Showing 40 of 1,388 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.